{
  "hash": "6c96fd5f875d11858a1c1597832bc3ab",
  "result": {
    "engine": "knitr",
    "markdown": "---\neditor_options: \n   chunk_output_type: console\n---\n\n\n\n# Drug Rebate Program {#sec-rebate}\n\n> __Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program__\n\nThe Table below, updated weekly, contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the __Drug Products in the Medicaid Drug Rebate Program (MDRP)__ database. Each file on this table represents a snapshot of data in the system and is not updated by subsequent changes. Once the covered outpatient drugs in each of these files appear in the quarterly MDRP database, the file will be removed from this table. States can utilize these files to identify newly reported covered outpatient drugs.\n\n## Metadata\n\n\n::: {.cell}\n<pre class=\"r-output\"><code>      [ROWS] 932 \n    [FIELDS] 17 \n  [MODIFIED] 2021-10-13 \n  [DOWNLOAD] https://data.medicaid.gov/sites/default/files/uploaded_resources/newly-reported-drugs-october-files.csv \n[DICTIONARY] https://data.medicaid.gov/api/1/metastore/schemas/data-dictionary/items/66f843c8-1180-4244-8adc-554d02584fa4 \n</code></pre>\n:::\n\n\n### Dictionary\n\n\n::: {.cell}\n<pre class=\"r-output\"><code><span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>ndc1</span>\n<span style='color: #555555;'>Labeler Code - First segment of National Drug Code\n(NDC1) that identifies the manufacturer, labeler,\nrelabeler, packager, repackager or distributor of\nthe drug.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>ndc2</span>\n<span style='color: #555555;'>Product Code - Second segment of National Drug\nCode (NDC2)</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>ndc3</span>\n<span style='color: #555555;'>Package Size - Third segment of National Drug Code\n(NDC3)</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>labeler_name</span>\n<span style='color: #555555;'>Labeler Name: Name of labeler as it appears on the\nsigned rebate agreement.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>labeler_status</span>\n<span style='color: #555555;'>Labeler Status: Active or Terminated</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>fda_name</span>\n<span style='color: #555555;'>The FDA Name should reflect the drug's name as\nreported to FDA; therefore, the FDA Name reported\nto CMS should correspond to the drug name on file\nwith the FDA.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>cod_status</span>\n<span style='color: #555555;'>Covered Outpatient Drug (COD) Status: A category\nthat identifies whether or not a product meets\nthe statutory definition of a covered outpatient\ndrug in accordance with sections 1927(k)(2) to\n1927(k)(4) of the Social Security Act. Numeric\nvalues; 8-digit field; format: MMDDYYYY. Valid\nValues: 01 = Abbreviated New Drug Application\n(ANDA) 02 = Biological License Application\n(BLA) 03 = New Drug Application (NDA) 04 = NDA\nAuthorized Generic 05 = DESI 5* - LTE/IRS drug\nfor all indications 06 = DESI 6* - LTE/IRS\ndrug withdrawn from market 07 = Prescription\nPre-Natal Vitamin or Fluoride 08 = Prescription\nDietary Supplement/Vitamin/Mineral (Other than\nPrescription Pre-Natal Vitamin or Fluoride) 09\n= OTC Monograph Tentative 10 = OTC Monograph\nFinal 11 = Unapproved Drug - Drug Shortage 12\n= Unapproved Drug - Per 1927(k)(2)(A)(ii) 13 =\nUnapproved Drug - Per 1927(k)(2)(A)(iii) Spaces\n= The Labeler has not reported this field to the\nMedicaid Drug Rebate Program. * NDCs with a COD\nStatus of DESI 5/6 are not eligible for coverage\nor rebates under the Medicaid Drug Rebate Program.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>fda_application_number</span>\n<span style='color: #555555;'>FDA Application Number/OTC Monograph Number: For\ndrugs with a COD status of ANDA, BLA, NDA, or\nNDA Authorized Generic, this is the application\nnumber (assigned by the FDA for approval to market\na drug or biological in the United States) under\nwhich the NDC is currently marketed. Numeric\nvalues; 7-digit field; padded with leading zeros\nas needed. For drugs with a COD status of OTC\nMonograph Tentative or Final, this is the FDA's\nregulatory citation for the OTC. Alpha-numeric\nvalues; 7-digit field. For drugs with a COD\nStatus of OTC Monograph Final, the first four\ncharacters are a constant of PART; the last\nthree characters are the numeric values for the\nappropriate regulatory citation for the product\n(e.g., 225). For drugs with a COD Status of OTC\nMonograph Tentative, the first four characters\nare a constant of PART; the last three characters\nare the numeric values for the appropriate\nregulatory citation for the product, or three\nzeros if a Monograph Number is not available.\nFor drugs with a COD Status other than ANDA, BLA,\nNDA, NDA Authorized Generic, OTC Monograph Final,\nor OTC Monograph Tentative, the FDA Application\nNumber/OTC Monograph Number field should be\nzero-filled.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>drug_category</span>\n<span style='color: #555555;'>Drug Category: This field indicates whether the\ndrug is single source (S), innovator multiple\nsource (I), or non-innovator multiple source (N).\n1-character field. Valid Values: N = Non-innovator\nmultiple source S = Single source I = Innovator\nmultiple source</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>drug_type</span>\n<span style='color: #555555;'>Drug Type: Identifies a drug as prescription (Rx)\nor Over-the-Counter (OTC). Numeric values; 1-digit\nfield. Valid Values: 1 = Rx 2 = OTC</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>line_extension</span>\n<span style='color: #555555;'>Line Extension Drug Indicator: Identifies whether\na product is a line extension drug as defined\nin Section 1927(c)(2)(C) of the Social Security\nAct, including whether the drug is excluded from\nthe statutory definition of a line extension on\nthe basis of being an abuse-deterrent formulation\n(ADF). If a labeler is seeking an ADF exclusion,\na value of R will appear in this field. Note:\nIf a Line Extension Drug Indicator has not been\nreported for an NDC, this field will be blank.\nValid Values: Y = Yes N = No (i.e., neither LE nor\nADF) R = Request for ADF Exclusion E = Excluded\n(Due to ADF) Note: This value may only be assigned\nby CMS</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>fda_approval_date</span>\n<span style='color: #555555;'>FDA Approval Date: NDA (including Authorized\nGeneric), ANDA or BLA approval date. For covered\noutpatient drugs for which the FDA does not\nrequire approval, the FDA Approval Date will be\n09/30/1990, or, if the drug was first marketed\nafter 09/30/1990, the actual date the drug was\nfirst marketed.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>market_date</span>\n<span style='color: #555555;'>Market Date: For S, I, and N drugs marketed under\nan FDA-approved application (e.g. BLA, NDA, ANDA),\nthe earliest date the drug was first marketed\nunder the application number by any labeler.\nFor drugs marketed without an FDA-approved\napplication (e.g. OTC monograph, unapproved drug),\nthe earliest date the drug was first marketed by\nany labeler. For all drugs (i.e., those marketed\nwith or without an FDA-approved application), if\na drug was purchased or otherwise acquired from\nanother labeler, the Market Date should be equal\nto the Market Date of the original product. If a\nMarket Date falls on a date that is earlier than\n9/30/1990, CMS will change it to 9/30/1990 in the\nMedicaid Drug Programs (MDP) system since dates\nearlier than the start of the Drug Rebate Program\nhave no bearing on the program.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>unit_type</span>\n<span style='color: #555555;'>Unit Type: One of the 10 unit types by which\na drug may be dispensed. 3-character field;\nleft-justified; blank-filled for Unit Type values\nwith fewer than 3 characters. Valid Values: AHF =\nInjectable Anti-Hemophilic Factor CAP = Capsule EA\n= Each GM = Gram MCI = Millicurie ML = Milliliter\nUCI = Microcurie SUP = Suppository TAB = Tablet\nTDP = Transdermal patch</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>unit_per_package_size</span>\n<span style='color: #555555;'>Units Per Package Size: The total number of\nunits in the smallest dispensable amount for the\n11-digit NDC. Numeric values; 11-digit field:\n7 whole numbers, the decimal point (.') and 3\ndecimal places; right-justified; zero-padded for\nUPPS values with fewer than 11 digits.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>therapeutic_equivalent_code</span>\n<span style='color: #555555;'>Therapeutic Equivalence Code (TEC): FDA-assigned\nTherapeutic Equivalence Codes as found in the\nFDA's Orange Book: Approved Drug Products with\nTherapeutic Equivalence Evaluations. Alpha-numeric\nvalues; 2-digit field. Valid Values: AA = Products\nin Conventional Dosage Forms Not Presenting\nBioequivalence Problems AB = Products Meeting\nNecessary Bioequivalence Requirements assigned an\nFDA TEC of AB, or AB1 through AB9 AN = Solutions\nand Powders for Aerosolization AO = Injectable Oil\nSolutions AP = Injectable Aqueous Solutions and,\nin Certain Instances, Intravenous Non-Aqueous AT\n= Topical Products BC = Extended-Release Dosage\nForms (Capsules, Injectables, and Tablets) BD =\nActive Ingredients and Dosage Form With Documented\nBioequivalence Problems BE = Delayed-Release Oral\nDosage Forms BN = Products in Aerosol-Nebulizer\nDrug Delivery Systems BP = Active Ingredients\nand Dosage Forms with Potential Bioequivalence\nProblems BR = Suppositories or Enemas That Deliver\nDrugs for Systemic Absorption BS = Products Having\nDrug Standard Deficiencies BT = Topical Products\nwith Bioequivalence Issues BX = Drug Products\nfor Which the Data Are Insufficient To Determine\nTherapeutic Equivalence NR = Not Rated</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>5i_indicator</span>\n<span style='color: #555555;'>The 5i Drug Indicator specifies whether or not the\nproduct is a 5i drug (i.e., inhaled, instilled,\nimplanted, injected, or infused). (Y or N)</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>purchased_product_date</span>\n<span style='color: #555555;'>Purchased Product Date (PPD): The date the company\ncurrently holding legal title to the NDC first\nmarkets the drug under this NDC (this date can\nresult, for example, from the purchase of an\nNDC from one company by another company, the\nre-designation of an NDC from one of a company's\nlabeler codes to another of that same company's\nlabeler codes, cross-licensing arrangements,\netc.). Zero or blank-filled for drugs without\nPurchased Product Dates.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>coverage_effective_date</span>\n<span style='color: #555555;'>The Coverage Effective Date field reflects the\ndate on which a product is first eligible for\ncoverage under the MDRP.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>drug_termination_date</span>\n<span style='color: #555555;'>Termination Date: The date on which the drug\nwas withdrawn from market or the drug's last lot\nexpiration date.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>drug_reactivation_date</span>\n<span style='color: #555555;'>Reactivation Date: The date on which a terminated\nproduct is re-introduced to the market.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>date_reported_to_cms</span>\n<span style='color: #555555;'>Date Reported to CMS: The date on which the\nproduct was initially reported to CMS via MDP</span>\n</code></pre>\n:::\n\n\n## Data\n\n\n::: {.cell}\n<pre class=\"r-output\"><code><span style='color: #555555;'># A tibble: 932 × 17</span>\n   ndc1  ndc2  ndc3  ndc11       fda_nameproduct_name                 cod_status\n   <span style='color: #555555; font-style: italic;'><chr></span> <span style='color: #555555; font-style: italic;'><chr></span> <span style='color: #555555; font-style: italic;'><chr></span> <span style='color: #555555; font-style: italic;'><chr></span>       <span style='color: #555555; font-style: italic;'><chr></span>                                <span style='color: #555555; font-style: italic;'><fct></span>     \n<span style='color: #555555;'> 1</span> 00006 5331  01    00006533101 WELIREG 40MG TABLET                  03        \n<span style='color: #555555;'> 2</span> 00093 3420  01    00093342001 CYCLOBENZAPRINE HCL 5MG TABLETS 100  01        \n<span style='color: #555555;'> 3</span> 00093 3421  01    00093342101 CYCLOBENZAPRINE HCL 7.5MG TABLETS 1… 01        \n<span style='color: #555555;'> 4</span> 00093 3422  01    00093342201 CYCLOBENZAPRINE HCL 10MG TABLETS 100 01        \n<span style='color: #555555;'> 5</span> 00093 3422  05    00093342205 CYCLOBENZAPRINE HCL 10MG TABLETS 500 01        \n<span style='color: #555555;'> 6</span> 00113 7032  40    00113703240 MINOXIDIL 5% 180 DAY LIQ 12OZ        01        \n<span style='color: #555555;'> 7</span> 00115 1010  03    00115101003 Baclofen 10MG                        01        \n<span style='color: #555555;'> 8</span> 00143 9361  01    00143936101 MICAFUNGIN LYO for INJ 50mg x 1      01        \n<span style='color: #555555;'> 9</span> 00143 9362  01    00143936201 MICAFUNGIN LYO for INJ 100mg x 1     01        \n<span style='color: #555555;'>10</span> 00378 0399  18    00378039918 Dimethyl Fumarate DR 240mg C  60s G… 01        \n<span style='color: #555555;'># ℹ 922 more rows</span>\n<span style='color: #555555;'># ℹ 11 more variables: fda_application_numberotc_monograph_number <chr>,</span>\n<span style='color: #555555;'>#   drug_category <fct>, drug_type <fct>, unit_type <fct>, upps <dbl>,</span>\n<span style='color: #555555;'>#   line_extension <chr>, tec_code <fct>, fda_approval_date <date>,</span>\n<span style='color: #555555;'>#   market_date <date>, termination_date <date>, date_transferred <date></span>\n</code></pre>\n:::\n\n\n### Overview\n\n\n::: {.cell}\n<pre class=\"r-output\"><code><span style='color: #0000BB;'>resp (932 rows and 17 variables, 16 shown)</span>\n\nID | Name                                       | Type        |    Missings\n---+--------------------------------------------+-------------+------------\n1  | ndc1                                       | character   |    0 (0.0%)\n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n---+--------------------------------------------+-------------+------------\n2  | ndc2                                       | character   |    0 (0.0%)\n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n---+--------------------------------------------+-------------+------------\n3  | ndc3                                       | character   |    0 (0.0%)\n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n---+--------------------------------------------+-------------+------------\n4  | ndc11                                      | character   |    0 (0.0%)\n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n---+--------------------------------------------+-------------+------------\n5  | fda_nameproduct_name                       | character   |    0 (0.0%)\n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n---+--------------------------------------------+-------------+------------\n6  | cod_status                                 | categorical |    0 (0.0%)\n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n---+--------------------------------------------+-------------+------------\n7  | fda_application_numberotc_monograph_number | character   |    0 (0.0%)\n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n---+--------------------------------------------+-------------+------------\n8  | drug_category                              | categorical |    0 (0.0%)\n   |                                            |             |            \n   |                                            |             |            \n---+--------------------------------------------+-------------+------------\n9  | drug_type                                  | categorical |    0 (0.0%)\n   |                                            |             |            \n---+--------------------------------------------+-------------+------------\n10 | unit_type                                  | categorical |    0 (0.0%)\n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n---+--------------------------------------------+-------------+------------\n11 | upps                                       | numeric     |    0 (0.0%)\n---+--------------------------------------------+-------------+------------\n13 | tec_code                                   | categorical |    0 (0.0%)\n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n---+--------------------------------------------+-------------+------------\n14 | fda_approval_date                          | date        |    0 (0.0%)\n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n---+--------------------------------------------+-------------+------------\n15 | market_date                                | date        |    0 (0.0%)\n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n---+--------------------------------------------+-------------+------------\n16 | termination_date                           | date        | 929 (99.7%)\n   |                                            |             |            \n   |                                            |             |            \n---+--------------------------------------------+-------------+------------\n17 | date_transferred                           | date        |    0 (0.0%)\n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n   |                                            |             |            \n---------------------------------------------------------------------------\n\nID |                                                Values |           N\n---+-------------------------------------------------------+------------\n1  |                                                 00006 |   1 ( 0.1%)\n   |                                                 00023 |   2 ( 0.2%)\n   |                                                 00024 |   8 ( 0.9%)\n   |                                                 00054 |   1 ( 0.1%)\n   |                                                 00074 |   1 ( 0.1%)\n   |                                                 00075 |   7 ( 0.8%)\n   |                                                 00088 |   1 ( 0.1%)\n   |                                                 00093 |  10 ( 1.1%)\n   |                                                 00113 |   6 ( 0.6%)\n   |                                                 00115 |   4 ( 0.4%)\n   |                                                 (...) |            \n---+-------------------------------------------------------+------------\n2  |                                                  0001 |   4 ( 0.4%)\n   |                                                  0002 |   1 ( 0.1%)\n   |                                                  0003 |   1 ( 0.1%)\n   |                                                  0005 |   1 ( 0.1%)\n   |                                                  0009 |   1 ( 0.1%)\n   |                                                  0010 |   1 ( 0.1%)\n   |                                                  0011 |   2 ( 0.2%)\n   |                                                  0012 |   2 ( 0.2%)\n   |                                                  0013 |   2 ( 0.2%)\n   |                                                  0014 |   5 ( 0.5%)\n   |                                                 (...) |            \n---+-------------------------------------------------------+------------\n3  |                                                    00 |  15 ( 1.6%)\n   |                                                    01 | 251 (26.9%)\n   |                                                    02 |  53 ( 5.7%)\n   |                                                    03 |  30 ( 3.2%)\n   |                                                    04 |  21 ( 2.3%)\n   |                                                    05 |  52 ( 5.6%)\n   |                                                    06 |  28 ( 3.0%)\n   |                                                    07 |  11 ( 1.2%)\n   |                                                    08 |   9 ( 1.0%)\n   |                                                    09 |  25 ( 2.7%)\n   |                                                 (...) |            \n---+-------------------------------------------------------+------------\n4  |                                           00006533101 |   1 ( 0.1%)\n   |                                           00023350731 |   1 ( 0.1%)\n   |                                           00023715160 |   1 ( 0.1%)\n   |                                           00024279201 |   1 ( 0.1%)\n   |                                           00024279401 |   1 ( 0.1%)\n   |                                           00024590800 |   1 ( 0.1%)\n   |                                           00024591000 |   1 ( 0.1%)\n   |                                           00024591900 |   1 ( 0.1%)\n   |                                           00024591902 |   1 ( 0.1%)\n   |                                           00024592000 |   1 ( 0.1%)\n   |                                                 (...) |            \n---+-------------------------------------------------------+------------\n5  | 2.5% Dextrose and 0.45% Sodium Chl Liquid 25 g 1000mL |   1 ( 0.1%)\n   |                                      Abiraterone Tabs |   1 ( 0.1%)\n   |                                Acetaminophen ER 650mg |   1 ( 0.1%)\n   |                          ACUVAIL 0.45% 30 x 0.4 mL FW |   1 ( 0.1%)\n   |                     Acyclovir 200mg/5ml, 473ml bottle |   1 ( 0.1%)\n   |                                               Aemcolo |   1 ( 0.1%)\n   |       AKOVAZ-EPHEDRINE SULFATE INJECTION 50MG/ML VIAL |   1 ( 0.1%)\n   |                                        AKOVAZ 50MG/ML |   1 ( 0.1%)\n   |      Alaway Preservative Free Antihistamine Eye Drops |   1 ( 0.1%)\n   |                            Albuterol Sulfate Inhalant |   1 ( 0.1%)\n   |                                                 (...) |            \n---+-------------------------------------------------------+------------\n6  |                                                    01 | 628 (67.4%)\n   |                                                    02 |  39 ( 4.2%)\n   |                                                    03 | 177 (19.0%)\n   |                                                    04 |  23 ( 2.5%)\n   |                                                    07 |   9 ( 1.0%)\n   |                                                    08 |   1 ( 0.1%)\n   |                                                    09 |  26 ( 2.8%)\n   |                                                    10 |  24 ( 2.6%)\n   |                                                    12 |   5 ( 0.5%)\n---+-------------------------------------------------------+------------\n7  |                                                       |  14 ( 1.5%)\n   |                                               0000000 |   1 ( 0.1%)\n   |                                               0014602 |   1 ( 0.1%)\n   |                                               0017422 |   1 ( 0.1%)\n   |                                               0017555 |   2 ( 0.2%)\n   |                                               0018074 |   1 ( 0.1%)\n   |                                               0018651 |   1 ( 0.1%)\n   |                                               0018741 |   2 ( 0.2%)\n   |                                               0018965 |   1 ( 0.1%)\n   |                                               0019018 |   1 ( 0.1%)\n   |                                                 (...) |            \n---+-------------------------------------------------------+------------\n8  |                                                     I | 105 (11.3%)\n   |                                                     N | 693 (74.4%)\n   |                                                     S | 134 (14.4%)\n---+-------------------------------------------------------+------------\n9  |                                                     1 | 856 (91.8%)\n   |                                                     2 |  76 ( 8.2%)\n---+-------------------------------------------------------+------------\n10 |                                                   AHF |   1 ( 0.1%)\n   |                                                   CAP | 149 (16.0%)\n   |                                                    EA |  74 ( 7.9%)\n   |                                                    GM |  55 ( 5.9%)\n   |                                                    ML | 209 (22.4%)\n   |                                                   SUP |   1 ( 0.1%)\n   |                                                   TAB | 439 (47.1%)\n   |                                                   TDP |   4 ( 0.4%)\n---+-------------------------------------------------------+------------\n11 |                                          [0.14, 1000] |         932\n---+-------------------------------------------------------+------------\n13 |                                                    A1 |   1 ( 0.1%)\n   |                                                    A3 |   4 ( 0.4%)\n   |                                                    AA |  31 ( 3.3%)\n   |                                                    AB | 539 (57.8%)\n   |                                                    AN |   8 ( 0.9%)\n   |                                                    AP | 103 (11.1%)\n   |                                                    AT |   5 ( 0.5%)\n   |                                                    BE |   1 ( 0.1%)\n   |                                                    BP |   1 ( 0.1%)\n   |                                                    NR | 239 (25.6%)\n---+-------------------------------------------------------+------------\n14 |                                            1990-09-30 |  57 ( 6.1%)\n   |                                            1991-10-31 |   3 ( 0.3%)\n   |                                            1991-12-23 |   5 ( 0.5%)\n   |                                            1992-02-10 |   1 ( 0.1%)\n   |                                            1992-06-19 |   2 ( 0.2%)\n   |                                            1992-07-31 |   2 ( 0.2%)\n   |                                            1992-10-29 |   2 ( 0.2%)\n   |                                            1993-03-29 |   2 ( 0.2%)\n   |                                            1993-10-01 |   1 ( 0.1%)\n   |                                            1993-12-16 |   1 ( 0.1%)\n   |                                                 (...) |            \n---+-------------------------------------------------------+------------\n15 |                                            1990-09-30 |  57 ( 6.1%)\n   |                                            1991-10-31 |   3 ( 0.3%)\n   |                                            1991-12-23 |   5 ( 0.5%)\n   |                                            1992-02-10 |   1 ( 0.1%)\n   |                                            1992-06-19 |   2 ( 0.2%)\n   |                                            1992-07-31 |   2 ( 0.2%)\n   |                                            1992-10-29 |   2 ( 0.2%)\n   |                                            1993-03-29 |   2 ( 0.2%)\n   |                                            1993-10-01 |   1 ( 0.1%)\n   |                                            1993-12-16 |   1 ( 0.1%)\n   |                                                 (...) |            \n---+-------------------------------------------------------+------------\n16 |                                            2018-02-10 |   1 (33.3%)\n   |                                            2018-06-06 |   1 (33.3%)\n   |                                            2022-03-31 |   1 (33.3%)\n---+-------------------------------------------------------+------------\n17 |                                            2021-07-26 |  19 ( 2.0%)\n   |                                            2021-07-27 |  24 ( 2.6%)\n   |                                            2021-07-28 |  36 ( 3.9%)\n   |                                            2021-07-29 |  70 ( 7.5%)\n   |                                            2021-07-30 |  29 ( 3.1%)\n   |                                            2021-07-31 |   1 ( 0.1%)\n   |                                            2021-08-02 |  22 ( 2.4%)\n   |                                            2021-08-03 |  13 ( 1.4%)\n   |                                            2021-08-04 |   2 ( 0.2%)\n   |                                            2021-08-11 |  42 ( 4.5%)\n   |                                                 (...) |            \n------------------------------------------------------------------------\n</code></pre>\n:::\n\n\n### Distribution\n\n\n::: {.cell}\n<pre class=\"r-output\"><code>Variable |  Mean |     SD | IQR |           Range | Skewness | Kurtosis |   n | n_Missing\n-----------------------------------------------------------------------------------------\nupps     | 86.62 | 185.27 |  99 | [0.14, 1000.00] |     3.60 |    13.55 | 932 |         0\n</code></pre>\n:::\n\n\n\n::: {.cell layout-ncol=\"2\"}\n::: {.cell-output-display}\n![](caid_rebate_files/figure-html/distribution_plot-1.png){width=672}\n:::\n:::\n\n",
    "supporting": [
      "caid_rebate_files"
    ],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {},
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}